The effect of bright light therapy on glycemic control and cortisol rhythmicity in depression: a randomized controlled trial

Background: Depressed patients with comorbid metabolic disorders have poorer quality of life and prognosis. Pharmacological interventions carries risks of liver and kidney toxicity, which highlights the need for safer non-pharmacological alternatives. Experimental data suggest that light exposure modulates cortisol secretion, thereby influencing metabolic outcomes in depression. We hypothesized that bright light therapy may ameliorate metabolic disturbances by modulating cortisol secretion.

Methods: In this randomized controlled trial, hospitalized patients with depression were assigned to receive either bright light therapy (BLT) or dim-light control condition. The pre−specified primary endpoint was the change in fasting blood glucose (FBG) and cortisol rhythm indices from baseline to post−treatment. Secondary endpoints included changes in other glycolipid parameters, and scores on the Hamilton Depression (HAMD) and Anxiety (HAMA) scales. Treatment effects were evaluated using linear mixed−effects models with baseline adjustment.

Results: After the 2−week intervention, the BLT group showed a significant reduction in fasting blood glucose (95% CI: 0.280 to 0.600; p < 0.001) and cortisol mesor (95% CI: −2.677 to −0.064; p = 0.040) compared to the control group. Within the BLT group, the change in FBG was positively associated with the change in cortisol mesor after adjusting for covariates (β = 0.053, 95% CI: 0.016 to 0.122, p = 0.036).

Conclusions: The findings of this study support a potential mechanism whereby BLT modulates cortisol rhythmicity, which in turn may contribute to improved glycemic control, pointing to its potential therapeutic benefit for addressing metabolic disturbances in depression.

Clinical Trial Registration: https://www.chictr.org.cn/bin/project/edit?pid=260569, identifier ChiCTR2500097364.

1 Introduction

Depression has become a significant cause of disability worldwide, adversely impacting both psychological well-being and physical health. Epidemiological data reveal an 88.52% surge in prevalence rates from 1990 to present, accompanied by a substantial rise in its disease burden worldwide (1, 2). Metabolic disturbances are another major health threat (3), epidemiologic evidence consistently indicates a comorbidity between depression and metabolic disturbances (4), with studies reporting a significantly higher prevalence of metabolic disturbances among depressed individuals compared to the controls (5). Patients with depression often exhibit various disease-specific physiological dysfunctions, including characteristic symptoms such as unbalanced dietary patterns, sleep disturbances, and significantly reduced physical activity levels (6). Certain behaviors associated with depression are established risk factors for Metabolic disturbances onset. Furthermore, standard pharmacological treatments for depressive disorders may directly influence multiple metabolic disturbances, potentially contributing to the identified clinical associations (7). It has been suggested that the metabolic disturbances (8), especially glycemic abnormalities, responds poorly to antidepressants, leading to a more chronic course in depressed patients (9, 10). Therefore, a non-pharmacological treatment is necessary.

Cortisol, a steroid hormone belonging to the glucocorticoid class, is primarily produced within the adrenal cortex’s zona fasciculata. The synthesis and release of this Hormones are precisely controlled by the hypothalamic–pituitary–adrenal (HPA) axis. Additionally, the secretion of cortisol follows a circadian pattern that aligns with the external alternation of light and darkness (11). Moreover, changes in cortisol levels are contingent upon the functional integrity of the suprachiasmatic nucleus (SCN) (12). Compelling evidence indicates that dysregulation of the HPA axis plays a significant role in the pathophysiology of depression during adulthood (13, 14). Cortisol secretion is altered in up to 80% of depressed patients (15), and cortisol levels are increased in depressed patients (16). There is evidence of a link between hypercortisolism and glycemic abnormalities (17). Increased cortisol secretion, reflecting potential HPA axis dysfunction, can contribute to elevated blood glucose levels (18).

Light is the most potent zeitgeber and a critical regulator of circadian rhythms (19). Light therapy, a non-pharmacological intervention known for its excellent safety record, has attracted increasing attention in recent years owing to its promising role in managing depressive disorders. As a complementary approach to pharmacotherapy for depression, a substantial body of research has confirmed its favorable efficacy and safety profile (20, 21). The underlying mechanism of this therapy is likely associated with its influence on circadian rhythm modulation, mediated via the SCN, which serves as the central pacemaker for circadian cycles in mammals. The SCN serves as a central regulator of multiple physiological functions, notably governing circadian rhythms such as sleep-wake patterns, thermoregulation, cardiovascular homeostasis, and neuroendocrine activity (including the release of cortisol) (22). By modulating SCN function, light therapy can effectively stabilize circadian rhythms, thereby alleviating depressive symptoms (23). Interestingly, growing evidence suggests an important link between circadian rhythm disruption and metabolic disturbances in humans (24–26). This connection is further supported by case reports documenting light therapy’s positive effects on glucose metabolism (27, 28) highlighting its potential dual role in both mood regulation and metabolic improvement, particularly in patients with mood disorders. Notably, one potential mechanism could be the role of light therapy in restoring normal cortisol regulation, given empirical evidence indicating its efficacy in attenuating hypercortisolemia in individuals with depression (29). These findings collectively suggest light therapy may offer a multifaceted therapeutic approach by simultaneously addressing mood disturbances and metabolic disturbances associated with circadian rhythm disruption.

Based on the rationale that light therapy shows promise in alleviating depressive symptoms but its effects on glucose and lipid metabolism and underlying physiological pathways remain unclear, we conducted a randomized controlled trial to test the following primary hypotheses: (H1) compared to dim light therapy, bright light therapy (BLT) will reduce fasting blood glucose levels in individuals with depression; (H2) BLT will reduce the mesor and amplitude of the circadian cortisol rhythm; and (H3) within the BLT group, changes in cortisol parameters will correlate with changes in fasting blood glucose and depressive symptoms.

2 Methods

2.1 Trial design

Eligible subjects enrolled in this randomized controlled trial were distributed, using a randomized approach, into two parallel groups: a bright light therapy intervention or a control condition. The participants were unaware of the grouping. The Psychological Hospital of Anhui Medical University Institutional Review Board (HFSY-IRB-YJ-KYXM-ZDM) approved of the study protocol. Upon enrollment, all volunteers provided their informed consent in writing after they received a complete overview of the experimental protocols and goals. Prior to commencement, this study was registered at the Chinese Clinical Trial Registry and assigned the trial ID ChiCTR2500097364.

2.2 Participants and enrollment criteria

The study cohort comprised 61 inpatients diagnosed with depression according to DSM-IV criteria. Participants were recruited from the Sleep Disorders Unit of the Psychological Hospital at Anhui Medical University between February and July 2025. Enrollment was strictly contingent upon meeting all predefined inclusion criteria: 1) aged between 18 and 65; 2) diagnosed with depression according to DSM-IV criteria; 3) graduated from elementary school or above; and 4) following a comprehensive explanation of the research protocol, written informed consent was obtained from all participants. Exclusion criteria encompassed: 1) a history of intellectual disability, organic brain injury, or other primary psychiatric conditions; 2) receipt of electroconvulsive therapy or transcranial magnetic stimulation within the three months prior to enrollment; 3) the presence of diagnosed systemic or neurological diseases—such as diabetes mellitus, thyroid disorders, hypertension, cardiac diseases, narrow-angle glaucoma, epilepsy, or dementia; 4) pregnancy (current, planned, or during breastfeeding); and 5) any ophthalmic pathology contraindicating phototherapy, such as cataracts, macular degeneration, glaucoma, retinal lesions, or blindness; 6)current smoking, drinking caffeinated beverages, using blood sugar-lowering or lipid-regulating drugs, and using drugs such as hydrocortisone or prednisone were not included in this research. However, former smokers were eligible if they had abstained for at least 6 months prior to enrollment. During the study, other medications were allowed.

2.3 Randomization, concealment and blinding

Randomization of participants to the bright light therapy versus the control group was performed via a centralized web-based platform. A computer-generated sequence was used to assign participants to their respective groups. To ensure concealment, this sequence was kept confidential until the interventions were administered, the participants remained unaware of their group assignment throughout the trial. Furthermore, An unblinded researcher was assigned tasks to administer and assign throughout the experiment, and all observers who scored behavior and performed data analysis were blinded to treatment assignment.

2.4 The intervention

2.4.1 Environmental light control and preparation

Prior to and throughout the intervention period, all participants adhered to a fixed sleep–wake schedule within the hospital ward. Ambient lighting was strictly controlled: illumination was maintained at approximately 400 lux from 06:00 to 22:00 and reduced to ≤ 20 lux from 22:00 to 06:00. Participants were admitted to the ward one day before baseline assessments to acclimatize and to avoid prolonged exposure to uncontrolled natural light.

2.4.2 Light therapy intervention

This intervention measure involves daily morning phototherapy for 14 days. A full-spectrum white light box (size: 25 × 50 cm; wavelengths > 450 nanometers of blue light are not filtered, color temperature: 6000K) is placed 50 cm above the participants’ heads at an angle. The illuminance at the eye level is measured using a photometer to calibrate the light intensity. Participants in the BLT group receive 10,000 lux of light, while those in the control group receive 100 lux of weak light. Each treatment lasts for 30 minutes and is conducted between 9 and 10 in the morning.

2.4.3 Saliva sampling

Trained nurses collected saliva samples from patients. On two consecutive days, saliva was collected at 8:00, 11:00, 14:00, 19:00, 20:00, 21:00, 22:00, 01:00, and 05:00. Saliva samples (≥1 ml) were collected using specialized tubes (Salivette^®, Sarstedt AG & Co, Nümbrecht, Germany) and preserved at -40 °C pending subsequent analysis. Participants were instructed to refrain from consuming caffeinated or alcoholic beverages throughout the sampling period. They were also advised to avoid tooth brushing or gum chewing for at least 15 minutes prior to each sample collection. Trained experimenters collected samples at night at the dimmest possible light degrees.

2.5 Assessment

2.5.1 Glucose and lipid metabolism indexes

Following an overnight fast, 5 mL of peripheral venous blood was collected both before and upon completion of the two-week light therapy intervention. Subsequent analysis of glucose and lipid metabolism indicators was performed by the hospital’s clinical laboratory.

2.5.2 Salivary cortisol measurement

Salivary cortisol concentrations were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (DRG International, Inc.) in strict accordance with the supplier’s instructions. The detection limit of the assay was 0.09 ng/mL. The intra-assay coefficient of variation (CV) was measured at 6.1% for a concentration of 3.08 ng/mL and decreased to 2.6% at 20.14 ng/mL. For inter-assay precision, the CV values were 13.6% at 0.64 ng/mL and 4.3% at 19.78 ng/mL.

2.5.3 Clinical symptoms

The Hamilton Anxiety Scale (HAMA) and Hamilton Depression Inventory (HAMD) are established tools for gauging anxiety and depression severity, respectively. The former contains 14 items, while the latter comprises 24 (30). The HAMA and HAMD scales, which range from 0 to 56, respectively, share a common scoring system where elevated scores correspond to a greater severity of symptomatology. In the HAMD, the total score for no depression is 0 ~ 8; mild to moderate depression is 21 ~ 35; and major depression is ≥ 36.

2.6 Side effects and adverse reactions

The assessment of possible adverse reactions and side effects after two weeks of light intervention was done and recorded by the psychiatrist (31).

2.7 Sample size

Utilizing G*Power 3.1, a minimum sample size was calculated based on a prior effect size estimate (Cohen’s d = 0.44) derived from a randomized controlled trial investigating light therapy in patients with type 2 diabetes and comorbid depression (32). The effect size corresponds to the between-group difference in fasting blood glucose observed at the end of the intervention period in that study. This calculation employed a two-tailed test with an alpha (α) level of 0.05 and was set to achieve a statistical power of 80%. The analysis indicated that 21 participants per group (total N = 42) were required. Accounting for an estimated 30% dropout rate (e.g., attrition, missing data), we planned to recruit 61 participants to ensure sufficient statistical power in the final analysis.

2.8 Statistical analysis

All analyses followed the intention-to-treat (ITT) principle. Baseline characteristics were compared using independent-samples t-tests (continuous variables) and chi-square tests (categorical variables), with data presented as mean ± standard. Based on the a priori hypothesis that BLT modulates cortisol secretion to improve metabolic dysregulation in depression, two primary analyses were pre-specified: (1) a linear mixed-effects model (LMM) to test the Group × Time interaction effect on FBG and cortisol mesor, and (2) within the BLT group, a multiple linear regression model examining the association between posttreatment changes in FBG and cortisol mesor, adjusted for age, sex, medication dosage (fluoxetine-equivalent), and illness duration. For all longitudinal outcomes, LMMs included a participant-specific random intercept and baseline covariates to estimate fixed effects for Group, Time, and their interaction. Secondary and exploratory analyses included LMMs for other metabolic and cortisol parameters, between-group comparisons of HAMD and HAMA scale scores, correlation analyses between cortisol and clinical changes, and sex-stratified sensitivity analyses.

We fitted a nonlinear model to the cortisol data from each participant using the function Y = mesor + amplitude × sin(2π × (X – acrophase)/24), where the wavelength (period) was constrained to 24 hours. All fittings were conducted with GraphPad Prism 8.0. The system derived essential circadian rhythm variables—namely the mesor, amplitude, acrophase, and the coefficient of determination (R²)—automatically through computation to quantify the precision of the cosine curve fitting. Based on the fitted model, individual salivary cortisol rhythm variables such as period, acrophase, amplitude, and mesor were subsequently extracted.

We utilized SPSS (version 25; IBM Corp) for all statistical computations and GraphPad Prism (version 8.0) for data visualization. Results were considered statistically significant if the p-value was below 0.05. A schematic diagram summarizing the study design and analysis pipeline is provided in Figure 1.

Figure 1

Figure 1. Study design and analysis pipeline. We collected the glycolipid metabolism indicators, salivary cortisol, and clinical scale data of 24 patients in the BLT group and 24 patients in the control group. We used group comparison and correlation analysis to explore the potential mechanism of bright light therapy in improving glucose and lipid metabolism in patients with depression. Abbreviations: BLT, bright light therapy; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; FBG, fasting blood FBG.

3 Results

3.1 The samples’ descriptive characteristics

In this randomized controlled trial, a total of 48 individuals diagnosed with depression were assigned to either a bright light treatment group or a control group, as outlined in the participant flow diagram (Figure 2). Each group comprised 24 participants, with the control condition including 7 male and 17 female participants, while the bright light intervention group consisted of 14 males and 10 females. The average age of participants in the bright light group was 42.17 years (SD = 11.72), compared to 39.38 years (SD = 13.63) in the control condition. We found no significant differences in baseline demographic and clinical variables, such as age, education, illness duration, smoking status, or alcohol use, between the groups. However, a significant gender discrepancy was noted (p = 0.042). With respect to clinical features, both groups showed comparable scores on the HAMD and HAMA scales at baseline. And all enrolled patients scored ≥ 21 on the HAMD, indicating moderate to severe depression and confirming they were above the clinical cutoff. Furthermore, the categories and dosages of antidepressant medications used were similar across groups, with no significant variations (see Table 1).

Figure 2

Figure 2. Study design diagram.

Table 1

Table 1. Demographic characteristics and clinical variables of the recruited subjects.

3.2 Adverse reactions

In the BLT group, two cases reported adverse reactions, resulting in an incidence rate of 8.3%. Among them, 1 case had dizziness and headache (symptoms disappeared after 2 d of treatment, and the patient insisted on completing the light therapy), and 1 case had slight blurred vision (symptoms disappeared after 1 d of treatment, and insisted on completing the light therapy). One case in the control group experienced adverse reactions, and the incidence of adverse reactions was 4.2%. Headache appeared (symptoms disappeared without treatment, adhering to the completion of light therapy), all adverse reactions were not given special treatment, and they relieved themselves within 2 d. The difference in the rates of adverse reactions between the groups was not statistically significant (p = 1.00).

3.3 Changes in key outcome indicators

A linear mixed model was used to analyze the changes in blood glucose, lipid metabolism indicators, and cortisol rhythm parameters. The results showed that in the BLT group, FBG, cortisol amplitude and mesor were significantly lower than those at baseline and in the control group after treatment (p < 0.05). Additionally, the HAMD scores of patients in the BLT group after intervention were also significantly lower, but no significant differences were observed in the other metabolic indicators within or between the groups (see Table 2).

Table 2

Table 2. Linear mixed model results for metabolic, cortisol, and clinical outcomes.

After further controlling for gender factors, the results of the mixed model still supported the above findings (see Supplementary Table 1). In the BLT group, there was still a significant group × time interaction effect for FBG, cortisol mesor, and amplitude (p < 0.05).

3.4 Association between posttreatment changes in fasting blood glucose and cortisol rhythm parameters within the bright light therapy group

After controlling for age, gender, disease duration and drug dosage, the multiple linear regression analysis showed that the change in fasting blood glucose in the BLT group after treatment was significantly positively correlated with the change in cortisol mesor (β = 0.053, 95% CI: 0.016 to 0.122, p = 0.036), but there was no significant correlation with the changes in amplitude, acrophase and period (see Table 3).

Table 3

Table 3. Association between posttreatment changes in fasting blood glucose and cortisol rhythm parameters within the bright light therapy group.

3.5 Association between posttreatment changes in cortisol rhythm parameters and Depression and Anxiety Symptoms within the two groups

The Pearson correlation analysis showed that in the BLT group, the changes in HAMD scores were significantly positively correlated with the changes in cortisol mesor and amplitude (r = 0.643, p = 0.018; r = 0.773, p = 0.003), but not with the changes in period and acrophase. In the control group, no significant correlation was observed between the cortisol rhythm parameters and the changes in HAMD or HAMA scores (see Table 4).

Table 4

Table 4. Association between posttreatment changes in cortisol rhythm parameters and Depression and Anxiety Symptoms within the two group.

3.6 Association between posttreatment changes in fasting blood glucose and depression symptoms within the two groups

After controlling for the gender factor, the partial correlation analysis showed that the change in HAMD score in the BLT group was moderately positively correlated with the change in fasting blood glucose (β = 0.531, 95% CI: 0.138 to 0.848, p = 0.042), while there was no significant correlation in the control group (see Table 5).

Table 5

Table 5. Association between posttreatment changes in FBG and Depression Symptoms within the two groups.

3.7 Gender stratification sensitivity analysis

To further explore the influence of gender on the therapeutic effect, we conducted a gender-stratified sensitivity analysis (see Supplementary Table 2). The results showed that in the female subgroup, the light therapy had a more significant improvement trend on fasting blood glucose (β = -1.346, p = 0.065), but it did not reach statistical significance; in the male subgroup, the above interaction effect was weaker.

4 Discussion

This study examined the impact of bright light therapy on circadian rhythm synchronization and metabolic health (glucose/lipid metabolism) in depressed individuals through a randomized controlled design. Conducted at a psychiatric specialist hospital, the study specifically enrolled hospitalized individuals with depressive disorders. Consequently, the findings are primarily applicable to the patient population receiving specialized psychiatric inpatient care.

The application of bright light therapy exerted a beneficial effect on glycemic control, manifested as lower fasting blood glucose in the depressed cohort, suggesting its potential to serve as an effective non-pharmacological approach for glycemic management. A tendency toward improved glucose regulation was noted in the BLT group compared to the control condition, lending support to prior findings reported by Nieuwenhuis and colleagues (27). A regimen of 10,000 lux light therapy, delivered in 30-minute increments over 10 sessions (totaling 10 hours), resulted in an immediate decline in blood glucose concentrations. The present investigation confirms that bright light intervention induces favorable alterations in glucose metabolism among subjects with depression. This finding is consistent with a growing consensus suggesting that modulating circadian rhythms is integral to metabolic health (33). In the control group, there was no improvement in blood glucose levels. This could be attributed to the fact that the exposure to low - intensity light in the control group was insufficient to drive meaningful circadian rhythm synchronization or metabolic regulation. High-intensity light, on the other hand, is a potent clock regulator that can acutely influence cortisol rhythms, thereby more effectively resetting SCN and downstream metabolic pathways. Research has indicated that high-intensity light therapy is more effective than low-intensity light therapy (34). However, interpretation of these results requires careful discussion of the potential confounding effects of antidepressant treatment. Since the effects of multiple psychotropic drugs on glucose metabolism are well documented, they are heterogeneous. The literature presents conflicting results on how antidepressants influence insulin sensitivity and glucose homeostasis, with divergent findings ranging from an elevated diabetes risk to neutral or even beneficial effects. It has also been found that the use of selective serotonin reuptake inhibitors (SSRIs) may improve glucose metabolism, whereas certain norepinephrine drugs may worsen glucose metabolism (35). During the initial weeks of therapy, SSRIs like sertraline and citalopram can enhance insulin sensitivity. Research suggests this transient benefit may result from serotonin’s role in regulating hepatic glucose output (36). Notably, the timing of metabolic assessment becomes critical. Because longitudinal studies have shown that long-term SSRI use (>6 months) may paradoxically increase diabetes risk through a cumulative effect on obesity (37). In summary, although our findings support bright light therapy as a promising adjunct to metabolic management of depression, pharmacological context remains an important moderator of effect. Clinical protocols should incorporate antidepressant pharmacogenomic analysis and continuous glucose monitoring to optimize personalized treatment strategies.

The current investigation failed to detect significant alterations in lipid metabolism, which may be attributed to the relatively short duration and moderate intensity of the light therapy regimen. This is consistent with a previous trial employing light therapy at 4000 lux for 5 hours per day, which reported elevated fasting triglyceride levels under bright light therapy compared to dim light (38). Accordingly, the notable lack of significant alteration in lipid measures could be attributable to the intensity and duration of light administered, a conclusion that warrants verification in subsequent research.

At the same time, we also found that the mesor and amplitude of cortisol decreased before and after the light therapy. At present, other study did not measure the circadian rhythm of cortisol by noninvasive acquisition, including detailed analysis of parameters such as period, amplitude, mesor, and acrophase. In the present trial, we administered bright light therapy (10,000 lux) for 30 minutes daily between 9:00 and 10:00 a.m. over a two-week period, with salivary cortisol sampled at nine timepoints across two consecutive days. This study used a detailed parametric analysis to comprehensively assess the rhythmicity of patients with depression before and after light intervention. The present data support and extend the findings previously reported by Kostoglou-Athanassiou and colleagues (39), regarding the cortisol-lowering effect of bright light therapy. However, the existing literature presents a complex picture, with studies also reporting increased (40, 41) or negligible changes (42–46) in cortisol levels following light exposure. This discrepancy suggests that key parameters such as treatment duration, light intensity, and timing relative to biological rhythms are critical moderators of cortisol response (47). This protocol differs from several prior studies that used longer daily exposure durations (e.g., 2–5 hours), varied timing of light exposure (e.g., morning vs. evening), or shorter intervention periods (e.g., single or several days). Such methodological variations—particularly in exposure timing relative to the circadian phase and total cumulative light dose—likely contribute to the heterogeneity in reported cortisol outcomes.

Our study also found that fasting blood glucose and the cortisol mesor after light therapy showed a strong correlation. Currently, the majority of existing research has emphasized the isolated impact of light therapy on either fasting blood glucose or cortisol levels, with limited investigation into their combined effects. Although the study of Jung, C. M., et al. focused on cortisol, it was mentioned that changes in cortisol levels may indirectly affect fasting blood glucose by affecting insulin sensitivity (47). Therefore, our findings suggest that the improvement in fasting blood glucose observed following bright light therapy is associated with changes in cortisol rhythmicity. Further experimental research is required to elucidate the underlying mechanisms through which cortisol influences insulin sensitivity. Additionally, the potential therapeutic efficacy of bright light therapy in managing dysglycemia among depressed individuals warrants investigation.

We further investigated the effect of bright light therapy on depressive symptoms. After the intervention with bright light, depressive symptoms were significantly alleviated, and this result was confirmed by Menegaz de Almeida’s previous retrospective study (48). Their systematic review included a meta-analysis of 11 randomized clinical trials, pooling data from over 850 participants. The study found that among the population using bright light therapy (at least 30 minutes per day, 10,000 lux of white light), the remission rate of non-seasonal depression was 41%. However, the improvement of anxiety symptoms was not obvious with light therapy, possibly because anxiety symptoms are closely related to sleep quality. More and more studies have shown that phototherapy can significantly improve the sleep quality of participants and alleviate symptoms related to anxiety (49, 50).

This investigation revealed that, following gender adjustment, higher HAMD scores were predictive of increased fasting blood glucose levels solely within the BLT group, a relationship not identified in the control group. This finding indicates that the observed association between light therapy and changes in fasting blood glucose may be related to alterations in cortisol regulation. This correlation was not present in controls, implying that the interaction between blood glucose and depressive symptoms may be state-dependent and require specific physiological conditions, such as bright light-induced hormonal changes, to manifest.

In the process of light therapy, a few patients experienced discomfort, such as dizziness and headache, but the symptoms were mild and transient and improved spontaneously without treatment. The overall adverse effect profile was favorable, in agreement with previously published data (51). During the light therapy, the patient did not have manic episodes and other adverse reactions.

The patients recruited in this study were all inpatients, and diet and exercise were strictly controlled. Thus, the influence of these factors on fasting blood glucose levels was avoided, which could affect the accuracy of the study results. Our study has several limitations. To begin with, the proportion of men was higher in the BLT group than in the control group after randomization (58% vs. 29%), and residual confounding is possible, although the multivariable regression model was adjusted for sex. Moreover, the sample was dominated by women (56%), which was inconsistent with the gender distribution of the general population and may affect the external validity of the results. However, some studies have also indicated that women are more sensitive to the impact of bright light on the circadian rhythm system, while the responses at lower light levels do not exhibit significant gender differences (52). And, the generalizability of these results is restricted by the single-center origin and modest number of participants. Enhancing the wider relevance of future findings will therefore require studies that are both multi-institutional and incorporate a more balanced sex representation. In the future, we can expand the sample size, strictly control the confounding factors, and explore the effects of different light parameters (such as light intensity, wavelength, irradiation time, etc.) on fasting blood glucose optimization. In addition, the exclusion of patients with other primary psychiatric conditions, while necessary to ensure internal validity and isolate the effects of bright light therapy on depression and metabolic parameters, may limit the generalizability of our findings to the broader population of depressed individuals with comorbid psychiatric disorders. Additionally, although we excluded current smokers, smoking history was included in our statistical models to account for potential long-term metabolic influences. Finally, the duration of this trial was limited; extended observation and additional studies are necessary to assess the long-term efficacy and safety profile of high-intensity light therapy in regulating blood glucose among depressed individuals.

5 Conclusion

This study demonstrates that bright light therapy can improve fasting glucose levels in individuals with depression, likely mediated through modulation of cortisol rhythmicity. These findings offer preliminary evidence supporting the therapeutic potential of BLT for glycemic management in depressed inpatients. Further validation through larger, multi-center trials—including outpatient populations and patients with confirmed metabolic syndrome—is warranted to establish its broader applicability.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Ethics Committee of the Fourth People’s Hospital of Hefei. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

JF: Conceptualization, Formal analysis, Methodology, Software, Writing – original draft, Writing – review & editing. XL: Conceptualization, Formal analysis, Software, Writing – review & editing. SZ: Data curation, Writing – review & editing. QH: Data curation, Writing – review & editing. TW: Data curation, Writing – review & editing. JY: Data curation, Writing – review & editing. DZ: Funding acquisition, Project administration, Supervision, Writing – review & editing. XQ: Methodology, Project administration, Supervision, Writing – review & editing.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the National Clinical Key Specialty Construction Project of China and the Hefei 7th cycle key specialty construction project, Anhui Provincial Health and Wellness Scientific Research Project (Grant Nos. AHWJ2023A20086 and AHWJ2024Aa20549).

Acknowledgments

We acknowledge the support of participants and the staff of the Department of Sleep Disorders, Affiliated Psychological Hospital of Anhui Medical University, and the Institute of Physical Science and Information Technology at Anhui University.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1743465/full#supplementary-material

References

1. Monroe SM and Harkness KL. Major depression and its recurrences: life course matters. Annu Rev Clin Psychol. (2022) 18:329–57. doi: 10.1146/annurev-clinpsy-072220-021440

PubMed Abstract | Crossref Full Text | Google Scholar

2. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. (2024) 403:2133–61. doi: 10.1016/S0140-6736(24)00757-8

PubMed Abstract | Crossref Full Text | Google Scholar

3. Eckel RH, Grundy SM, and Zimmet PZ. The metabolic syndrome. Lancet. (2005) 365:1415–28. doi: 10.1016/S0140-6736(05)66378-7

PubMed Abstract | Crossref Full Text | Google Scholar

4. Marazziti D, Rutigliano G, Baroni S, Landi P, Dell'Osso L, et al. Metabolic syndrome and major depression. CNS Spectrums. (2014) 19:293–304. doi: 10.1017/S1092852913000667

PubMed Abstract | Crossref Full Text | Google Scholar

5. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care. (2012) 35:1171–80. doi: 10.2337/dc11-2055

PubMed Abstract | Crossref Full Text | Google Scholar

6. Strine TW, Mokdad AH, Dube SR, Balluz LS, Gonzalez O, Berry JT, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatry. (2008) 30:127–37. doi: 10.1016/j.genhosppsych.2007.12.008

PubMed Abstract | Crossref Full Text | Google Scholar

7. McIntyre RS, Park KY, Law CWY, Sultan F, Adams A, Lourenco MT, et al. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs. (2010) 24:741–53. doi: 10.2165/11533280-000000000-00000

PubMed Abstract | Crossref Full Text | Google Scholar

8. Penninx BWJH and Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dial Clin Neurosci. (2018) 20:63–73. doi: 10.31887/DCNS.2018.20.1/bpenninx

PubMed Abstract | Crossref Full Text | Google Scholar

9. Vogelzangs N, Beekman ATF, van Reedt Dortland AKB, Schoevers RA, Giltay EJ, de Jonge P, et al. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology. (2014) 39:1624–34. doi: 10.1038/npp.2014.9

PubMed Abstract | Crossref Full Text | Google Scholar

10. Marijnissen RM, Vogelzangs N, Mulder ME, van den Brink RHS, Comijs HC, and Oude Voshaar RC. Metabolic dysregulation and late-life depression: a prospective study. Psychol Med. (2017) 47:1041–52. doi: 10.1017/S0033291716003196

PubMed Abstract | Crossref Full Text | Google Scholar

11. do Amaral FG and Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch Endocrinol Metab. (2018) 62:472–9. doi: 10.20945/2359-3997000000066

PubMed Abstract | Crossref Full Text | Google Scholar

12. Ishida A, Mutoh T, Ueyama T, Bando H, Masubuchi S, Nakahara D, et al. Light activates the adrenal gland: timing of gene expression and glucocorticoid release. Cell Metab. (2005) 2:297–307. doi: 10.1016/j.cmet.2005.09.009

PubMed Abstract | Crossref Full Text | Google Scholar

13. Kennis M, Gerritsen L, van Dalen M, Williams A, Cuijpers P, and Bockting C. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. (2020) 25:321–38. doi: 10.1038/s41380-019-0585-z

PubMed Abstract | Crossref Full Text | Google Scholar

14. Zajkowska Z, Gullett N, Walsh A, Zonca V, Pedersen GA, Souza L, et al. Cortisol and development of depression in adolescence and young adulthood - a systematic review and meta-analysis. Psychoneuroendocrinology. (2022) 136:105625. doi: 10.1016/j.psyneuen.2021.105625

PubMed Abstract | Crossref Full Text | Google Scholar

15. Thomson F and Craighead M. Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem Res. (2008) 33:691–707. doi: 10.1007/s11064-007-9518-3

PubMed Abstract | Crossref Full Text | Google Scholar

16. Knorr U, Vinberg M, Kessing LV, and Wetterslev J. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology. (2010) 35:1275–86. doi: 10.1016/j.psyneuen.2010.04.001

PubMed Abstract | Crossref Full Text | Google Scholar

17. Ortiz R, Kluwe B, Odei JB, Echouffo Tcheugui JB, Sims M, Kalyani RR, et al. The association of morning serum cortisol with glucose metabolism and diabetes: The Jackson Heart Study. Psychoneuroendocrinology. (2019) 103:25–32. doi: 10.1016/j.psyneuen.2018.12.237

PubMed Abstract | Crossref Full Text | Google Scholar

18. Lehrer HM, Dubois SK, Maslowsky J, Laudenslager ML, and Steinhardt MA. Hair cortisol concentration and glycated hemoglobin in African American adults. Psychoneuroendocrinology. (2016) 72:212–8. doi: 10.1016/j.psyneuen.2016.06.018

PubMed Abstract | Crossref Full Text | Google Scholar

19. Brown TM, Brainard GC, Cajochen C, Czeisler CA, Hanifin JP, Lockley SW, et al. Recommendations for daytime, evening, and nighttime indoor light exposure to best support physiology, sleep, and wakefulness in healthy adults. PloS Biol. (2022) 20:e3001571. doi: 10.1371/journal.pbio.3001571

PubMed Abstract | Crossref Full Text | Google Scholar

20. Mårtensson B, Pettersson A, Berglund L, and Ekselius L. Bright white light therapy in depression: A critical review of the evidence. J Affect Disord. (2015) 182:1–7. doi: 10.1016/j.jad.2015.04.013

PubMed Abstract | Crossref Full Text | Google Scholar

21. Perera S, Eisen R, Bhatt M, Bhatnagar N, de Souza R, Thabane L, et al. Light therapy for non-seasonal depression: systematic review and meta-analysis. BJPsych Open. (2016) 2:116–26. doi: 10.1192/bjpo.bp.115.001610

PubMed Abstract | Crossref Full Text | Google Scholar

22. Li X and Li X. The antidepressant effect of light therapy from retinal projections. Neurosci Bull. (2018) 34:359–68. doi: 10.1007/s12264-018-0210-1

PubMed Abstract | Crossref Full Text | Google Scholar

23. Huang S-Y, Koo M, Hsieh T-C, Lee R-P, and Sung H-C. Effect of bright light therapy on depressive symptoms in middle-aged and older patients receiving long-term hemodialysis. Int J Environ Res Public Health. (2020) 17:7763. doi: 10.3390/ijerph17217763

PubMed Abstract | Crossref Full Text | Google Scholar

24. Garaulet M, Ortega FB, Ruiz JR, Rey-López JP, Béghin L, Manios Y, et al. Short sleep duration is associated with increased obesity markers in European adolescents: effect of physical activity and dietary habits. The HELENA study. Int J Obes (Lond). (2011) 35:1308–17. doi: 10.1038/ijo.2011.149

PubMed Abstract | Crossref Full Text | Google Scholar

25. Takahashi JS, Hong H-K, Ko CH, and McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. (2008) 9:764–75. doi: 10.1038/nrg2430

PubMed Abstract | Crossref Full Text | Google Scholar

26. Bass J and Takahashi JS. Circadian integration of metabolism and energetics. Science. (2010) 330:1349–54. doi: 10.1126/science.1195027

PubMed Abstract | Crossref Full Text | Google Scholar

27. Nieuwenhuis RF, Spooren PFMJ, and Tilanus JJD. Less need for insulin, a surprising effect of phototherapy in insulin-dependent diabetes mellitus. Tijdschr Psychiatr. (2009) 51:693–7.

PubMed Abstract | Google Scholar

28. Allen NH, Kerr D, Smythe PJ, Martin N, Osola K, and Thompson C. Insulin sensitivity after phototherapy for seasonal affective disorder. Lancet. (1992) 339:1065–6. doi: 10.1016/0140-6736(92)90594-S

PubMed Abstract | Crossref Full Text | Google Scholar

29. Lieverse R, Van Someren EJW, Nielen MMA, Uitdehaag BMJ, Smit JH, and Hoogendijk WJG. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Arch Gen Psychiatry. (2011) 68:61–70. doi: 10.1001/archgenpsychiatry.2010.183

PubMed Abstract | Crossref Full Text | Google Scholar

30. Williams JB. Standardizing the Hamilton Depression Rating Scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci. (2001) 251 Suppl 2:II6–12. doi: 10.1007/BF03035120

PubMed Abstract | Crossref Full Text | Google Scholar

31. Kogan AO and Guilford PM. Side effects of short-term 10,000-lux light therapy. Am J Psychiatry. (1998) 155:293–4. doi: 10.1176/ajp.155.2.293

PubMed Abstract | Crossref Full Text | Google Scholar

32. Brouwer A, van Raalte DH, Nguyen H-T, Rutters F, van de Ven PM, Elders PJM, et al. Effects of light therapy on mood and insulin sensitivity in patients with type 2 diabetes and depression: results from a randomized placebo-controlled trial. Diabetes Care. (2019) 42:529–38. doi: 10.2337/dc18-1732

PubMed Abstract | Crossref Full Text | Google Scholar

33. Chen R, Yan Y, and Cheng X. Circadian light therapy and light dose for depressed young people: a systematic review and meta-analysis. Front Public Health. (2024) 11:1257093. doi: 10.3389/fpubh.2023.1257093

PubMed Abstract | Crossref Full Text | Google Scholar

34. Jiang L, Zhang S, Wang Y, So KF, Ren C, Tao Q, et al. Efficacy of light therapy for a college student sample with non-seasonal subthreshold depression: An RCT study. J Affect Disord. (2020) 277:443–9. doi: 10.1016/j.jad.2020.08.055

PubMed Abstract | Crossref Full Text | Google Scholar

35. Olguner Eker Ö, Özsoy S, Eker B, and Doğan H. Metabolic effects of antidepressant treatment. Noro Psikiyatr Ars. (2017) 54:49–56. doi: 10.5152/npa.2016.12373

PubMed Abstract | Crossref Full Text | Google Scholar

36. Alruwaili NS, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Ragab AE, Alenazi AA, et al. Antidepressants and type 2 diabetes: highways to knowns and unknowns. Diabetol Metab Syndr. (2023) 15:179. doi: 10.1186/s13098-023-01149-z

PubMed Abstract | Crossref Full Text | Google Scholar

37. Isaac R, Boura-Halfon S, Gurevitch D, Shainskaya A, Levkovitz Y, and Zick Y. Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells. J Biol Chem. (2018) 293:4577–8. doi: 10.1074/jbc.AAC118.002476

PubMed Abstract | Crossref Full Text | Google Scholar

38. Versteeg RI, Stenvers DJ, Visintainer D, Linnenbank A, Tanck MW, Zwanenburg G, et al. Acute effects of morning light on plasma glucose and triglycerides in healthy men and men with type 2 diabetes. J Biol Rhythms. (2017) 32:130–42. doi: 10.1177/0748730417693480

PubMed Abstract | Crossref Full Text | Google Scholar

39. Kostoglou-Athanassiou I, Treacher DF, Wheeler MJ, and Forsling ML. Bright light exposure and pituitary hormone secretion. Clin Endocrinol (Oxf). (1998) 48:73–9. doi: 10.1046/j.1365-2265.1998.00355.x

PubMed Abstract | Crossref Full Text | Google Scholar

40. Scheer FA and Buijs RM. Light affects morning salivary cortisol in humans. J Clin Endocrinol Metab. (1999) 84:3395–8. doi: 10.1210/jcem.84.9.6102

PubMed Abstract | Crossref Full Text | Google Scholar

41. Leproult R, Colecchia EF, L’Hermite-Balériaux M, and Van Cauter E. Transition from dim to bright light in the morning induces an immediate elevation of cortisol levels. J Clin Endocrinol Metab. (2001) 86:151–7. doi: 10.1210/jcem.86.1.7102

PubMed Abstract | Crossref Full Text | Google Scholar

42. Rüger M, Gordijn MCM, Beersma DGM, de Vries B, and Daan S. Time-of-day-dependent effects of bright light exposure on human psychophysiology: comparison of daytime and nighttime exposure. Am J Physiol Regul Integr Comp Physiol. (2006) 290:R1413–1420. doi: 10.1152/ajpregu.00121.2005

PubMed Abstract | Crossref Full Text | Google Scholar

43. Leproult R, Van Reeth O, Byrne MM, Sturis J, and Van Cauter E. Sleepiness, performance, and neuroendocrine function during sleep deprivation: effects of exposure to bright light or exercise. J Biol Rhythms. (1997) 12:245–58. doi: 10.1177/074873049701200306

PubMed Abstract | Crossref Full Text | Google Scholar

44. Thalén BE, Mørkrid L, Kjellman BF, and Wetterberg L. Cortisol in light treatment of seasonal and non-seasonal depression: relationship between melatonin and cortisol. Acta Psychiatr Scand. (1997) 96:385–94. doi: 10.1111/j.1600-0447.1997.tb09934.x

PubMed Abstract | Crossref Full Text | Google Scholar

45. McIntyre IM, Norman TR, Burrows GD, and Armstrong SM. Melatonin, cortisol and prolactin response to acute nocturnal light exposure in healthy volunteers. Psychoneuroendocrinology. (1992) 17:243–8. doi: 10.1016/0306-4530(92)90063-d

PubMed Abstract | Crossref Full Text | Google Scholar

46. Lavoie S, Paquet J, Selmaoui B, Rufiange M, and Dumont M. Vigilance levels during and after bright light exposure in the first half of the night. Chronobiol Int. (2003) 20:1019–38. doi: 10.1081/cbi-120025534

PubMed Abstract | Crossref Full Text | Google Scholar

47. Jung CM, Khalsa SB, Scheer FA, Cajochen C, Lockley SW, Czeisler CA, et al. Acute effects of bright light exposure on cortisol levels. J Biol Rhythms. (2010) 25:208–16. doi: 10.1177/0748730410368413

PubMed Abstract | Crossref Full Text | Google Scholar

48. Menegaz de Almeida A, Aquino de Moraes FC, Cavalcanti Souza ME, Cavalcanti Orestes Cardoso JH, Tamashiro F, Miranda C, et al. Bright light therapy for nonseasonal depressive disorders: A systematic review and meta-analysis. JAMA Psychiatry. (2025) 82:38–46. doi: 10.1001/jamapsychiatry.2024.2871

PubMed Abstract | Crossref Full Text | Google Scholar

49. Millot F, Endomba FT, and Forestier N. Light therapy in post-traumatic stress disorder: A systematic review of interventional studies. J Clin Med. (2024) 13:3926. doi: 10.3390/jcm13133926

PubMed Abstract | Crossref Full Text | Google Scholar

50. Sit DK, McGowan J, Wiltrout C, Diler RS, Dills JJ, Luther J, et al. Adjunctive bright light therapy for bipolar depression: A randomized double-blind placebo-controlled trial. Am J Psychiatry. (2018) 175:131–9. doi: 10.1176/appi.ajp.2017.16101200

PubMed Abstract | Crossref Full Text | Google Scholar

51. Xiao M, Feng L, Wang Q, Luan X, Chen S, and He J. The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. Int J Geriatr Psychiatry. (2021) 36:182–9. doi: 10.1002/gps.5412

PubMed Abstract | Crossref Full Text | Google Scholar

52. Vidafar P, McGlashan EM, Burns AC, Anderson C, Shechter A, Lockley SW, et al. Greater sensitivity of the circadian system of women to bright light, but not dim-to-moderate light. J Pineal Res. (2024) 76:e12936. doi: 10.1111/jpi.12936

PubMed Abstract | Crossref Full Text | Google Scholar